In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft

NMR in Biomedicine

Volumn 21, Issue 7, 2008, Pages 723-733

  Lee, Seung Cheol ^a   Huang, Ming Q ^a   Nelson, David S ^a   Pickup, Stephen ^a   Wehrli, Suzanne ^b   Adegbola, Onikepe ^a   Poptani, Harish ^a   Delikatny, Edward J ^a   Glickson, Jerry D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

1H MRS; 31p MR'S; Chemotherapy response; CHOP; Ki67; Lactate; Non Hodgkin's lymphoma; Proliferation

Indexed keywords

RECONNAISSANCE AIRCRAFT;

1H MRS; 31P MR'S; CHEMOTHERAPY RESPONSE; CHOP; DIFFUSE LARGE B-CELL LYMPHOMA; IN-VIVO; KI67; LACTATE; NON-HODGKIN'S LYMPHOMA; PROLIFERATION;

CHEMOTHERAPY;

CHOLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; LACTIC ACID; MOLECULAR MARKER; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATASE; PHOSPHORUS; PREDNISONE; VINCRISTINE SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; LARGE CELL LYMPHOMA; LONGITUDINAL STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; SCID MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLINE; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, SCID; NUCLEOTIDES; PHOSPHATIDYLETHANOLAMINES; TIME FACTORS; TISSUE EXTRACTS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANAS; ANIMALIA; MUS;

EID: 50049118887     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1250     Document Type: Article

References (62)

1. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society: Atlanta, 2006.
2. Rosen ST, Molina A, Winter JN, Gordon LI, Nicolaou N. Non-Hodgkin's lymphoma. In Cancer Management: A Multidisciplinary Approach, Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds). The Oncology Group, a division of SCP Communications, Inc.: New York, 2003; 665-712.
3. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol. Clin. North. Am. 2004; 42: 1083-1100.
4. 31P MRS in situ. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 1545-1551.
5. Bryant DJ, Bydder GM, Case HA, Collins AG, Cox IJ, Makepeace A, Pennock JM. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in non-Hodgkin lymphoma. J. Comput. Assist. Tomogr. 1988; 12: 770-774.
6. 31P magnetic resonance spectroscopy. Br. J. Cancer. 1990; 61: 485-490.
7. 31P magnetic resonance spectroscopy study in non-Hodgkin's lymphoma. Br. J. Radiol. 1991; 64: 923-928.
8. 13P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Br. J. Cancer. 1991; 63: 953-958.
9. Dixon RM. NMR studies of phospholipid metabolism in hepatic lymphoma. NMR Biomed. 1998; 11: 370-379.
10. Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 1995; 55: 3286-3294.
11. Griffiths JR, Tate AR, Howe FA, Stubbs M. Magnetic Resonance Spectroscopy of cancer: practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur. J. Cancer 2002; 38: 2085-2093.
12. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad. Radiol. 2004; 11: 368-376.
13. Arias-Mendoza F, Zakian K, Schwartz A, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR. Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies. NMR Biomed. 2004; 17: 382-391.
14. Gadian DG. NMR and its applications to living systems, 2nd edn. Oxford University Press: New York, 1996.
15. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002; 94: 1197-1203.
16. McKnight TR. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin. Oncol. 2004; 31: 605-617.
17. Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin. Prostate Cancer 2004; 3: 174-181.
18. 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol. 2002; 75: 959-966.
19. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn. Reson. Med. 2005; 54: 43-50.
20. 1H NMR spectroscopy of subcutaneous tumors in mice: preliminary studies of effects of growth, chemotherapy and blood flow reduction. NMR Biomed. 1992; 5: 296-302.
21. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 635-639.
22. 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat. Res. 1998; 150: 38-42.
23. 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res. 1998; 58: 1063-1067.
24. Poptani H, Bansal N, Graham RA, Mancuso A, Nelson DS, Glickson JD. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed. 2003; 16: 102-111.
25. Mauch PM, Armitage JO, Harris NL, Dalla-Favera R, Coiffier B. Non-Hodgkin's Lymphomas, 3rd edn. Lippincott Williams & Wilkins: New York, 2003.
26. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gauland P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
27. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res. 2000; 6: 4950-4956.
28. He Q, Shungu DC, van Zijl PC, Bhujwalla ZM, Glickson JD. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J. Magn. Reson. B. 1995; 106: 203-211.
29. Frahm J, Merboldt KD, Hanicke W. Localized proton spectroscopy using stimulated echoes. J. Magn. Reson. 1987; 72: 502-508.
30. Ordidge RJ, Connelly A, Lohman JAB. Image-Selected in Vivo Spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson. 1986; 66: 283-294.
31. Trautschold I, Lamprecht W, Schweitzer G. UV-method with hexokinase and glucose-6-phosphate dehydrogenase. In Methods of Enzymatic Analysis, Vol 7, 3rd edn, Bergmeyer HU (ed.). VCH: Weinheim, 1983; 346-357.
32. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed. 2005; 18: 430-439.
33. 1H magnetic resonance spectroscopy. Neoplasia 2006; 8: 560-567.
34. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
35. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 2003; 95: 1624-1633.
36. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006; 66: 427-434.
37. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
38. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66: 8927-8930.
39. 13C NMR spectroscopy. NMR Biomed. 1998; 11: 395-404.
40. Nielsen FU, Daugaard P, Bentzen L, Stodkilde-Jorgensen H, Overgaard J, Horsman MR, Maxwell RJ. Effect of changing tumor oxygenation on glycolytic metabolism in a murine C3H mammary carcinoma assessed by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 2001; 61: 5318-5325.
41. 13C magnetic resonance spectroscopy, Eppendorf electrode, and redox scanning. Cancer Res. 2003; 63: 8813-8820.
42. Rivenzon-Segal D, Margalit R, Degani H. Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. Am. J. Physiol. Endocrinol. Metab. 2002; 283: E623-630.
43. Terpstra M, Gruetter R, High WB, Mescher M, DelaBarre L, Merkle H, Garwood M. Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 1998; 58: 5083-5088.
44. 31P MRS of experimental tumours. NMR Biomed. 1993; 6: 345-365.
45. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
46. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell Biochem. 2003; 90: 525-533.
47. 1H spectroscopic imaging. Clin. Cancer Res. 2003; 9: 4529-4536.
48. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 2001; 84: 1016-1022.
49. Bhujwalla ZM, Shungu DC, Glickson JD. Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging. Magn. Reson. Med. 1996; 36: 204-211.
50. 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J. Biol. Chem. 2003; 278: 45915-45923.
51. Bui T, Thompson GB. Cancer's sweet tooth. Cancer Cell 2006; 9: 419-420.
52. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-434.
53. Neeman M, Degani H. Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. Cancer Res. 1989; 49: 589-594.
54. 31P NMR studies of RIF-1 fibrosarcoma cells perfused in vitro. NMR Biomed. 1996; 9: 173-178.
55. Smith TA, Eccles S, Ormerod MG, Tombs AJ, Titley JC, Leach MO. The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. Br. J. Cancer 1991; 64: 821-826.
56. Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed. 1993; 6: 318-323.
57. Delikatny EJ, Lander CM, Jeitner TM, Hancock R, Mountford CE. Modulation of MR-visible mobile lipid levels by cell culture conditions and correlations with chemotactic response. Int. J. Cancer 1996; 65: 238-245.
58. 1H-MRS lipid signal modulation and morphological and ultra-structural changes related to tumor cell proliferation. Magn. Reson. Med. 1999; 42: 248-257.
59. Barba I, Cabanas ME, Arus C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res. 1999; 59: 1861-1868.
60. 1H MR visible lipid in human glioma cells is independent of the cell cycle. Int. J. Oncol. 1997; 11: 543-550.
61. Poptani H, Pickup S, Delikatny EJ, Magnitsky S, Mancuso A, Nelson DS, Glickson JD. Increased diffusion coefficient correlates with decreased choline in response to cyclophosphamide therapy of RIF-1 tumors. Proc. Intl. Soc. Mag. Reson. Med. 2004; 2035.
62. 18F-FDG. J. Nucl. Med. 2005; 46: 945-952.